Brief: Seelos Therapeutics Provides Update On Top-Line Results From Its Amyotrophic Lateral Sclerosis Study With SLS-005 (IV Trehalose)

Seelos Therapeutics

19/03/2024 12:18

March 19 (Reuters) - Seelos Therapeutics Inc  SEEL.O :
    * SEELOS THERAPEUTICS PROVIDES UPDATE ON TOP-LINE RESULTS
FROM ITS
AMYOTROPHIC LATERAL SCLEROSIS (ALS) STUDY WITH SLS-005 (IV
TREHALOSE)
    * SEELOS THERAPEUTICS INC: PLAN TO REQUEST A MEETING WITH
FDA TO
DISCUSS POTENTIAL NEXT STEPS FOR PROGRAM
    * SEELOS THERAPEUTICS INC: STUDY DID NOT MEET STATISTICAL
SIGNIFICANCE IN PRIMARY AND SECONDARY ENDPOINT IN FULL ANALYSIS
SET
    * SEELOS: IMBALANCE OF DEATHS/DEATH EQUIVALENTS OBSERVED IN
STUDY,
WITH MORE EVENTS SEEN IN SLS-005 GROUP VERSUS PLACEBO
    * SEELOS THERAPEUTICS INC: SLS-005 WAS GENERALLY
WELL-TOLERATED
AND COMPARABLE TO PLACEBO IN SAFETY

Source text for Eikon:  ID:nPn8cKMRfa 
Further company coverage:  SEEL.O